Ruti Aga Gets Six Years: A Forged Prescription, a Clinic That Never Existed, and a Two-Year Ban That Quadrupled

September 10. Two dates collide in Ruti Aga's file — the March half marathon in China that she won and where the sample was collected, and September 10, the day her provisional suspension began. The Athletics Integrity Unit's announcement on Thursday puts the six-year figure at the top, but the heaviest fact sits elsewhere: a prescription written by a family member posing as a doctor, a clinic that did not exist, and an old prescription pad that the clinic itself disowned in writing. The tape disagreed with the table, so I kept watching — and what emerged reads less like a doping story and more like a medical-governance failure with a doping charge attached. Aga is no marginal name. The 2026 Tokyo Marathon is hers, along with three second-place finishes at World Marathon Majors. Her Berlin 2026 run was 2:18:34 — a figure absent from the AIU statement and drawn from my own records, so treat it as context, not evidence. The context matters because Ethiopia's women's marathon does not auto-select a 2:18 athlete; an entire cohort below 2:16 stands in front of her. In that depth, removing one runner changes national-team capacity by nothing measurable. The March race she won was a Chinese Label road race — elite women's field, in-competition testing, otherwise no AIU sample would exist. On the roads, the testing window opens at 23:59 the day before the race. That single technical detail is the door to this entire case, and it is exactly where a large share of the reporting slipped. Start with the chemistry, because the media misread the fact. Calling methylprednisolone a "prohibited steroid" is wrong. It is a glucocorticoid, class S9 on the WADA Prohibited List, and S9 is prohibited in-competition only — by injection, oral or rectal route. Anabolic steroids sit in S1 and are banned at all times. The legal consequence is direct: the dispute turns on route and timing, not on steroid use. A therapeutic knee injection is fully legal out of competition and becomes a violation only when residues are present in competition. Intra-articular methylprednisolone for knee synovitis is standard sports medicine in distance runners, and a knee injury is precisely the explanation Aga offered. Now the sanction arithmetic, because six years explains nothing on its own. Two years for the presence violation — a Specified Substance finding without proven intent, which is the standard tariff. Four years for tampering — the Code's standard sanction. Two plus four equals six. That sum is proof the panel rejected the no-significant-fault mitigation that would have cut the presence sanction, and it also tells you that backdating to September 10 is no discount. Provisional suspension time counts against the ban; the athlete gains nothing in real terms. The forged-prescription chain contains three independent verification failures. The clinic did not exist. The person who wrote the prescription held no medical registration and was a family member. He claimed to have used an old prescription pad from a former workplace, and the clinic explicitly disowned that claim. The paper failed at three separate points. The tampering charge rests not on the document alone but on statements given in an investigative interview, which means it came out of questioning. This is where I have to turn on my own trade. A javelin spreadsheet and a spare-room microphone in Hackney gave me one habit: attach a source line to every number. That habit broke in the coverage of this case. The substance was filed as a steroid, and from there the reflexive read — six years is excessive for a glucocorticoid — built itself. Both errors share a root: a misclassified drug. Four of those six years have nothing to do with the substance; they belong to the paperwork. And that is where I test my own favourite angle. Does the "disproportionate enforcement against African road runners" argument survive here? It does not, because the length of the ban was set by the document, not the drug. The day the tampering charge is removed from a case like this, the argument becomes valid. Not today. Three of us, one desk, and a tournament taught me in 2026 to build a list of disciplinary outcomes and look for the pattern. It was visible then and it is visible now: East African road-running cases that escalate to tampering almost always begin in the same place — an injured runner, an informal medic, and appearance-fee income that needs protecting. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners, and the incentive to mask pain is real. This athlete appears to have had no credentialed team physician, no TUE process, and no route-specific washout plan. When manufacturing paper looks cheap and keeping records looks expensive, people manufacture paper. The lapse is individual; the infrastructure around it is collective. One thing the statement does not say, and the reader has to hold the gap: the scope of disqualification. Standard AIU practice is automatic annulment of the competition where the sample was collected, including prize money, plus forfeiture of ranking points accrued after that date. What happened to the March win is nowhere in the text. What is in the text is that the 2026 Tokyo title and the three Major second places predate the violation and are not automatically erased, absent a finding of earlier use. That distinction is not small. It decides whether the 2:18 marathoner survives in the record. The forward question is not about ban length. Six years at 32 removes the 2028 Olympic cycle entirely and points to a return near 38, which in Ethiopian women's marathon depth is functionally a closed door. The real question is whether the next 2:19 runner with a sore knee has a credentialed doctor, a filed record and a TUE — or the same old prescription pad. The agent and management who accepted that document are not named anywhere in the AIU statement. That silence says something about who this sport punishes and who it leaves alone.